Systems biological assessment of T cell responses to vaccination
T 细胞对疫苗接种反应的系统生物学评估
基本信息
- 批准号:10584571
- 负责人:
- 金额:$ 37.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-07 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAdjuvantAdultAlgorithmsAllelesAllergic ReactionAntibioticsAntibody Binding SitesB-LymphocytesBloodCOVID-19COVID-19 vaccinationCOVID-19 vaccineCellsClinical TrialsDefectEpitopesExposure toFerritinFrequenciesGoalsGroupingHumanHypersensitivityImmuneImmunologicsIndividualLabelLymphocyteMessenger RNAMethodsNatural ImmunityOrganoidsPeptide/MHC ComplexPeptidesPfizer-BioNTech COVID-19 vaccinePhenotypeProbabilityRNA vaccinationRNA vaccineRabiesReportingSamplingSequence AnalysisSpecificityStainsSubunit VaccinesSurveysT cell responseT-LymphocyteT-cell receptor repertoireTechniquesTechnologyUniversitiesVaccinationVaccinesVertebral columnadaptive immunityantigen-specific T cellsbiological systemscohortcombinatorialcomplementarity-determining region 3draining lymph nodefallsgut microbiotainfluenza virus vaccinemicrobiomemicrobiotanovelphenotypic biomarkerresponseseasonal influenzasuccesstoolvaccine responseyoung adult
项目摘要
ABSTRACT – Project 2
The goal of Project 2 is to assess T cell responses in the context of proposed studies of: (i) COVID-19
vaccines that utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine) and (ii)
Humans given broad spectrum antibiotics that disrupt their microbiome, prior to and during rabies vaccination.
This goal is highly synergistic with those of Projects 1 and 3, which will evaluate innate and B cell responses
respectively, in the context of the same clinical trials. We will use new developed state-of-the-art techniques
that will allow us to probe the vaccine responses here with an unprecedented scale and depth. The three
methods are: (1) spheromer probes for specific T cells, (2) GLIPH (for Grouping of Lymphocyte Interactions by
Paratope Hotspots) analysis of TCR specificity groups, and (3) immune organoids. We will apply these tools in
the following aims:
Aim 1: Assessment of T cell responses to vaccination against COVID-19.
Sub-aim 1a. Analyze T cell responses induced by the BNT162b2 mRNA vaccine in healthy versus atopic
individuals. We will use the spheromer technology mentioned above, to create and use a panel of pMHC
Spheromers SARS-CoV-2 spike epitopes covering the major class I and II HLA alleles, to analyze the T cell
response, in healthy versus atopic subjects. In addition, we will perform TCR repertoire analysis using GLIPH2
to analyze both bulk and single cell TCR sequences in order to define the frequency, phenotype, function and
TCR diversity of antigen specific T cell responses to primary and secondary vaccination in blood and the
draining lymph nodes of both healthy adults and allergy prone subjects.
Sub-aim 1b: Assessment of T cell responses induced by the Novavax Matrix-M adjuvanted subunit vaccine.
We will also analyze samples collected from a Novavax sponsored trial done at the University of Witwatersrand
with spheromers and TCR sequence analysis and determine how the response to an adjuvanted subunit
vaccine differs from that induced by mRNA vaccination
Aim 2: Assessment of the impact of the microbiota on the antigen-specific T cell response to
vaccination. We will assess the impact of broad-spectrum antibiotics on the primary T cell response to rabies
vaccination. In particular, we will analyze the TCR repertoire and phenotype of T cells responding to this
vaccine, since there are clear indications that the microbiome can influence T cell phenotype, and we
hypothesize that there might be an influence on the repertoire as well.
摘要-项目2
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark Morris Davis其他文献
Mark Morris Davis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark Morris Davis', 18)}}的其他基金
Systems biological assessment of T cell responses to vaccination
T 细胞对疫苗接种反应的系统生物学评估
- 批准号:
10419280 - 财政年份:2022
- 资助金额:
$ 37.9万 - 项目类别:
Molecular interception and immunological characterization of age-associated disease
年龄相关疾病的分子拦截和免疫学表征
- 批准号:
10190562 - 财政年份:2021
- 资助金额:
$ 37.9万 - 项目类别:
High resolution longitudinal immune monitoring for elucidating immune aging dynamics
高分辨率纵向免疫监测阐明免疫衰老动态
- 批准号:
10190557 - 财政年份:2021
- 资助金额:
$ 37.9万 - 项目类别:
High resolution longitudinal immune monitoring for elucidating immune aging dynamics
高分辨率纵向免疫监测阐明免疫衰老动态
- 批准号:
10491673 - 财政年份:2021
- 资助金额:
$ 37.9万 - 项目类别:
High resolution longitudinal immune monitoring for elucidating immune aging dynamics
高分辨率纵向免疫监测阐明免疫衰老动态
- 批准号:
10687219 - 财政年份:2021
- 资助金额:
$ 37.9万 - 项目类别:
Molecular interception and immunological characterization of age-associated disease
年龄相关疾病的分子拦截和免疫学表征
- 批准号:
10687228 - 财政年份:2021
- 资助金额:
$ 37.9万 - 项目类别:
Molecular interception and immunological characterization of age-associated disease
年龄相关疾病的分子拦截和免疫学表征
- 批准号:
10491684 - 财政年份:2021
- 资助金额:
$ 37.9万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 37.9万 - 项目类别: